The U.S. Food and Drug Administration has cleared ArteraAI Breast for use in patients with early-stage, hormone receptor (HR)-positive, human epidermal growth factor receptor 2…
Continue Reading
News Source: medicalxpress.com
FDA clears ArteraAI Breast for breast cancer risk stratification
Leave a Reply